Hashimoto's Thyroiditis: Causes, Antibodies & Treatment

Named in 1912, Still Misunderstood in 2025

Japanese surgeon Hakaru Hashimoto described four patients with a distinctive form of thyroid inflammation in 1912, publishing his findings in a German surgical journal. He called it "struma lymphomatosa." It took decades for the medical community to recognize it as an autoimmune disease — the first autoimmune condition ever identified in humans. Today, Hashimoto's thyroiditis (also called Hashimoto's disease or chronic lymphocytic thyroiditis) accounts for roughly 90% of hypothyroidism in iodine-sufficient countries and affects an estimated 14 million Americans, with women outnumbering men 7:1.

The disease follows a variable course. Some patients develop progressive hypothyroidism over years. Others fluctuate between hypothyroid and hyperthyroid phases — a phenomenon called "Hashitoxicosis" — as damaged follicles release stored thyroid hormone before production capacity is fully lost.

The Autoimmune Mechanism

In Hashimoto's, the immune system mounts an attack against thyroid tissue through both antibody-mediated and cell-mediated pathways. CD4+ T-helper cells become sensitized to thyroid antigens and recruit cytotoxic CD8+ T-cells to destroy follicular cells. Simultaneously, B-cells produce autoantibodies against two primary targets.

• Thyroid peroxidase (TPO) antibodies: present in 90–95% of Hashimoto's patients; TPO enzyme is essential for thyroid hormone synthesis
• Thyroglobulin (TgAb) antibodies: present in 60–80% of patients; thyroglobulin is the protein backbone from which T3 and T4 are cleaved
• TSH receptor antibodies (blocking type): less common, but can directly inhibit TSH signaling

Antibody levels don't reliably predict symptom severity or rate of progression to overt hypothyroidism, a point that frustrates both patients and clinicians. High antibodies with normal TSH is common; the immune attack may remain largely subclinical for years.

Genetic and Environmental Triggers

Heritability studies suggest 70–80% of susceptibility to autoimmune thyroid disease is genetic. The HLA-DR3 and HLA-DR5 haplotypes show the strongest associations, as do variants in CTLA-4, PTPN22, and CD25 genes — all immune checkpoint regulators. But genetics explain only part of the picture.

Environmental triggers are actively studied. Iodine excess has a dose-response relationship with thyroid autoimmunity: populations transitioning from iodine deficiency to sufficiency via supplementation programs show measurable increases in Hashimoto's incidence, as excess iodine makes thyroglobulin more immunogenic. Selenium deficiency is mechanistically relevant because the thyroid has the highest selenium concentration per gram of any tissue, and selenoprotein glutathione peroxidase protects thyroid cells from hydrogen peroxide generated during hormone synthesis.

Selenium Supplementation: What the Trials Actually Show

Selenium's role in Hashimoto's has attracted genuine clinical interest since a 2002 German randomized controlled trial by Gärtner et al. showed that 200 mcg/day of selenomethionine for 3 months reduced TPO antibody levels by 36% in selenium-replete hypothyroid patients. Follow-on trials have largely replicated the antibody-lowering effect.

The 2021 Cochrane-style systematic review by Winther et al. analyzed 18 randomized trials involving 1,totalling 2,023 patients. Selenium supplementation consistently reduced TPO antibodies by 20–40%. The critical question — whether antibody reduction translates to improved clinical outcomes, slower progression to overt hypothyroidism, or better quality of life — remains underexplored. Most trials were short-term and used surrogate markers. The European Thyroid Association's 2017 guidelines recommend considering 200 mcg/day selenomethionine for 6–12 months in TPO-positive patients with a measured selenium level below the optimal range (115–120 mcg/L in serum).

The Gluten Connection: Evidence and Controversy

The proposed link between Hashimoto's and celiac disease has real biological grounding — both are autoimmune diseases, both involve intestinal permeability issues, and the prevalence of celiac disease is 2–5 times higher in Hashimoto's patients than in the general population. Gliadin proteins in wheat share structural similarities with thyroid antigens, raising molecular mimicry hypotheses.

The clinical question is whether a gluten-free diet benefits Hashimoto's patients without confirmed celiac disease. The evidence is limited. A 2019 randomized controlled trial by Sategna-Guidetti and colleagues showed TPO antibody reductions in celiac patients who went gluten-free; effects in non-celiac Hashimoto's patients are less established. Anecdotal and survey-based reports of symptom improvement are common but subject to significant placebo effects. The ATA does not currently recommend routine gluten-free diets for Hashimoto's in the absence of celiac diagnosis.

This article is for informational purposes only. Consult a qualified healthcare professional.